Preclinical studies on Sushi-IL15-Apo, a triple recombinant protein conjugated with polipoprotein A-I to bind to SR-BI on tumor cells, displayed improved ADCC activity against a tumor of this chimeric protein [114]. This evidence concerns the gene IL15 and neoplasm.